NCT03710122 is a Phase 2, PHASE3 clinical trial of Vancomycin in Primary Sclerosing Cholangitis, sponsored by Elizabeth Carey.

Who is sponsoring NCT03710122?

NCT03710122 is sponsored by Elizabeth Carey.

What drugs are being tested in NCT03710122?

Interventions in NCT03710122: Vancomycin, Placebo.

What condition does NCT03710122 study?

NCT03710122 studies Primary Sclerosing Cholangitis.

Is NCT03710122 still recruiting?

NCT03710122 is currently completed. Last updated 22 August 2025.

Last reviewed 2025-08-22 · How we verify

NCT03710122

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Vancomycin for Primary Sclerosing Cholangitis

Completed Phase 2, PHASE3 Last updated 22 August 2025

What this trial tests

Phase 2, PHASE3 trial testing Vancomycin in Primary Sclerosing Cholangitis in 102 participants. Completed in 20 March 2025.

Timeline

23 January 2020

Primary endpoint
3 March 2025

20 March 2025

Quick facts

Lead sponsor	Elizabeth Carey
Phase	Phase 2, PHASE3
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	triple
Primary purpose	treatment
Enrollment	102
Start date	23 January 2020
Primary completion	3 March 2025
Estimated completion	20 March 2025
Sites	4 locations across United States

Drugs / interventions tested

Vancomycin (vancomycin) — full drug profile →
Placebo

Conditions studied

Primary Sclerosing Cholangitis — all drugs for Primary Sclerosing Cholangitis →

Sponsor

Elizabeth Carey — full company profile →

Who can join

Adults 18 to 76, any sex, with Primary Sclerosing Cholangitis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To find out if vancomycin is a safe and effective therapy for primary sclerosing cholangitis. Funding Source - FDA OOPD

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Oral Vancomycin, Ursodeoxycholic Acid, or No Therapy for Pediatric Primary Sclerosing Cholangitis: A Matched Analysis.
Deneau MR, Mack C, Mogul D, Perito ER, et al · · 2021 · cited 65× · PMID 32946600 · DOI 10.1002/hep.31560
The Gut-Liver Axis in Cholestatic Liver Diseases.
Blesl A, Stadlbauer V. · · 2021 · cited 58× · PMID 33801133 · DOI 10.3390/nu13031018
Primary Biliary Cholangitis and Primary Sclerosing Cholangitis: Current Knowledge of Pathogenesis and Therapeutics.
Park JW, Kim JH, Kim SE, Jung JH, et al · · 2022 · cited 41× · PMID 35740310 · DOI 10.3390/biomedicines10061288
Primary sclerosing cholangitis.
Rabiee A, Silveira MG. · · 2021 · cited 40× · PMID 33824933 · DOI 10.21037/tgh-20-266
Management of primary sclerosing cholangitis and its complications: an algorithmic approach.
Prokopič M, Beuers U. · · 2021 · cited 30× · PMID 33377990 · DOI 10.1007/s12072-020-10118-x
The Management of Cholestatic Liver Diseases: Current Therapies and Emerging New Possibilities.
Mazzetti M, Marconi G, Mancinelli M, Benedetti A, et al · · 2021 · cited 17× · PMID 33919600 · DOI 10.3390/jcm10081763
Role of intestinal flora in primary sclerosing cholangitis and its potential therapeutic value.
Li ZJ, Gou HZ, Zhang YL, Song XJ, et al · · 2022 · cited 16× · PMID 36504550 · DOI 10.3748/wjg.v28.i44.6213
Microbial Players in Primary Sclerosing Cholangitis: Current Evidence and Concepts.
Özdirik B, Schnabl B. · · 2024 · cited 13× · PMID 38109970 · DOI 10.1016/j.jcmgh.2023.12.005

Verify or expand the search:

Other trials of Vancomycin

Trials testing the same drug.

NCT07435051 — Prospective, Randomized, Multicenter Clinical Trial of Bisphosphonates Combined With Vancomycin for the Treatment of Cie · Phase 3 · not yet recruiting
NCT06567808 — Prevention of Infections in Cardiac Surgery (PICS): a Cluster-randomized Factorial Cross-over Trial · Phase 4 · not yet recruiting
NCT06702345 — Clostridioides Difficile Controlled Human Infection Model · NA · not yet recruiting
NCT06716749 — Effectiveness of Adding Morphine to Intraosseous Vancomycin for Pain Control in Total Knee Arthroplasty · Phase 2 · completed
NCT06439953 — Irrisept Solution for Instrumented Spine Surgery · NA · recruiting

Other recruiting trials for Primary Sclerosing Cholangitis

Currently open trials in the same condition.

NCT07229911 — A Study of TAK-781 in Healthy Volunteers and in Participants With Non-Cirrhotic Primary Sclerosing Cholangitis (PSC) · Phase 1 · recruiting
NCT06905054 — Pharmacologic Approaches to Preventing Primary Sclerosing Cholangitis Recurrence After Liver Transplantation · Phase 2 · recruiting
NCT06455280 — A Study of SIPLIZUMAB in AILD and LT Patients · Phase 1 · recruiting
NCT06519162 — Liver-gut Axis Study Through Identification of Liver Disease-specific Microbiome · recruiting
NCT06351696 — The Effects of Bromelain Supplement in Patients With Ulcerative Colitis · NA · recruiting

Other Elizabeth Carey trials

Trials by the same sponsor.

NCT03722576 — Vidofludimus Calcium for Primary Sclerosing Cholangitis · Phase 2 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03710122 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Elizabeth Carey
Last refreshed: 22 August 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03710122.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing